Trial Profile

Antibody Response to Human Papillomavirus Recombinant Vaccine (Gardasil) in Girls and Young Women With Chronic Kidney Disease

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 10 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
Indications Cervical cancer; Human papillomavirus infections
Focus Pharmacodynamics

Most Recent Events

01 Sep 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
26 May 2010 Planned number of patients changed from 45 to 60 as reported by ClinicalTrials.gov.
26 May 2010 Planned end date changed from 1 Aug 2010 to 1 Jun 2011 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com